[Cibirrigmavog]

Sharron,I dont know if this will help,you can email them?.ZAR

TAMPA, FL--(MARKET WIRE)--Aug 2, 2007 -- Stem Cell Therapy International, Inc. (OTC BB:SCII.OB - News), a leading research and development company in the regenerative medicine field, announced today that it has acquired the exclusive worldwide rights to a new, U.S. Patent Pending anti-rejection umbilical cord blood stem cell technology. Calvin Cao, CEO of Stem Cell Therapy International and co-inventor of the new technology, explained why this new stem cell procedure is so important: "Stem cell treatments are transplants of cells, which is different than the transplant of entire organs such as the kidney or liver. In the case of organ transplants, many patients die each year because a 'matching' donor cannot be found in time. If a technology could be developed in which every organ was a 'match,' it would be a major achievement in medical science. This new method of transplanting umbilical cord stem cells that are considered compatible for anyone could, in some cases, actually replace costly and complicated organ transplants. Stem cell transplants are far simpler procedures in which stem cells are injected to stimulate the production of new cells in the affected organ
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the treatment of patients with stem cell transplantation therapy. SCTI manufactures the stem cell biological solutions that is currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established license agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI plans to provide these stem cell biological solutions to universities, institutes and privately funded laboratory facilities in the United States for research purposes and clinical trials. Its products, which are available now for treatment, include various stem cell biological solutions which contain human stem cells, low-molecular proteins and human growth factor hormones.
----------------
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the treatment of patients with stem cell transplantation therapy. SCTI manufactures the stem cell biological solutions that is currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established license agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI plans to provide these stem cell biological solutions to universities, institutes and privately funded laboratory facilities in the United States for research purposes and clinical trials. Its products, which are available now for treatment, include various stem cell biological solutions which contain human stem cells, low-molecular proteins and human growth factor hormones.

Stem Cell Therapy International
Media Relations
Peter K. Sidorenko
Chief Operating Officer
T: 813-600-0088
E: peter@scticorp.com